| Prev Close | 73.26 |
| Open | 74.38 |
| Day Low/High | 73.36 / 74.55 |
| 52 Wk Low/High | 60.89 / 85.97 |
| Volume | 12.51M |
| Avg Volume | 22.29M |
Gilead Sciences Inc. (GILD)
74.40
1.14
1.56
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 1.25B |
| Market Cap | 94.25B |
| EPS | 4.20 |
| P/E Ratio | 19.27 |
| Div & Yield | 2.72 (3.30%) |
Cramer: Don't Just Stand There Like Bambi; Sell Some
Stocks in the health care sector seem to have no underpinnings whatsoever.
Cramer: Health Care Sector Is Hurting
You can't ignore the evidence.
My Takeaways and Observations
 A short "Takeaways" today as I have to prepare for some morning meetings.  Down, up, down -- in a relatively volatile session.  I am comfortable with yesterday's bearish moves.  I sold more (short) today on the surprising (at least to me!) ramp...
My Takeaways and Observations (Early Edition)
Don't get excited by Take Under Monday.  The technical picture is mixed.  A stronger U.S. dollar presents multi-national vulnerability. This is consistent with Goldman Sachs lowering their three-year S&P 500 profits picture.  Peak Sports Viewer...
Gilead Sciences Getting Some Analyst Love
It's nice to see some positive analyst commentary on Gilead Sciences this week. The biotech stalwart has had Buy ratings reiterated at three analyst firms in recent days. Also, earlier this week Gilead posted very positive results from trials around...
It's Not Easy Being Green: 3 Solid Names That Stand Out
Look for solid companies showing life.
My Takeaways and Observations
The media is not the message. With a little help from Johnny Mercer, did you know he founded Capitol Records? Â This is serious folks -- I see less of a reason to have an outsized long portfolio than at any time since Winter 2007. The market outlook...
Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide
On days like this, the money just keeps sloshing around.
These Dogs Are Becoming Cool Cats
The dreck of the first half will be the gems of year end.
My Takeaways and Observations
It was a nostalgic morning. A 20th anniversary. My first TST column in 1997. There was no rest for the weary as the crude and oil markets turned on a dime after OPEC announced a production cut. I, Jim Cramer and others are skeptical about this - s...
Four Stellar Stocks to Beat the Biotech Slump
Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum
Cramer: Here Are the Reasons the Market Is Hated
Apart from the Fed, there are other factors that make investors nervous.
You've Got the Brains, I've Got the Book, Let's Make Lots of Money
Emulate Graham and Buffett with Greenblatt’s 'Magic Formula' screen.
Gilead: Horse of a Different, uh, Color
The once-mighty biotech has fallen, but entry opportunities will surface.
3 Stocks That Could Still Rally
It's been a nasty decline, but if we rally, these three have best charts.
Dive Safely Into These 12 Dividend Payers
If and when interest rates go up, this basket of stocks should continue to do well.
U.S. Stocks Gain Steam Despite Declines in Oil; GE Acquires 3D Printing Companies
U.S. stocks rose Tuesday, as oil prices added one percent on hopes of a production freeze among the world's biggest oil producers.
Gilead Sciences Could Be in For a Share Slump
Gilead may be a value trap as investors grow frustrated after two years of stagnant growth.
Gilead Sciences Shares Slide on Leerink Price Target Cut
Shares of Gilead Sciences were lower Wednesday after Leerink cut its price target on the shares.
Biotechs Continue to Lead a Listless Market
Stocks are back to flat to slightly lower overall, but biotechs are up some 1.5% following the announcement from Pfizer of plans to buy Medivation for $14 billion. Gilead Sciences is getting some flak for not pursuing Medivation more heavily, but I ...
Pfizer Is Buying Medivation for $14 Billion
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Watch Gilead for Buying Opportunities
There is a case for a low already being in place.
Gilead and Teva: Off-the-Charts Cheap
Rarely do investors get to buy these types of quality businesses at such discounted prices.
Cramer: Here's What to Embrace and What to Shun
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
